Objective:

To describe the effectiveness and safety of remdesivir in patients with SARS-CoV-2 pneumonia in real-world clinical practice conditions.

Method:

Retrospective observational study that included all adults with SARS-CoV-2 pneumonia admitted at the Moisès Broggi Hospital and treated with remdesivir between July 1st and November 7th, 2020. Efficacy outcomes were time to recovery, 28-day mortality, length of hospital stay, and the need of mechanical ventilation after treatment. The main safetyrelated endpoint was elevation of transaminases after treatment.

Results:

A total of 111 patients were included of whom 97 (87.4%) were receiving low-flow oxygen therapy. Median time to recovery was 9 days [6-14]. Seven patients (6.3%) died at 28 days’ follow-up. Median length of hospital stay was 12 days [9-22] and 15 patients (13.5%) needed mechanical ventilation after treatment with remdesivir. Severe hypertransaminasemia was observed in 4 patients (4%).

Conclusions:

Clinical outcomes of patients with SARS-CoV-2 pneumonia on low-flow oxygen therapy treated with remdesivir were similar to those published in clinical trials, both in terms of time to recovery and 28-day mortality.